275 related articles for article (PubMed ID: 33934279)
1. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
Wojciechowski P; Wilson K; Nazir J; Pustułka I; Tytuła A; Smela B; Pochopien M; Vredenburg M; McCrae KR; Jurczak W
Adv Ther; 2021 Jun; 38(6):3113-3128. PubMed ID: 33934279
[TBL] [Abstract][Full Text] [Related]
2. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.
Liu Y; Zhang HX; Su J; Geng QC; Lin X; Feng CX
Acta Haematol; 2023; 146(3):173-184. PubMed ID: 36572014
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
Yang R; Lin L; Yao H; Ji O; Shen Q
Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
[TBL] [Abstract][Full Text] [Related]
5. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
[TBL] [Abstract][Full Text] [Related]
6. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
[TBL] [Abstract][Full Text] [Related]
7. Fostamatinib or Thrombopoietin for the Treatment of Chronic Immune Thrombocytopenia in Adult Patients: A Real-World Assessment of Safety, Effectiveness and Cost.
Dranitsaris G; Peevyhouse A; Wood T; Kreychman Y; Neuhalfen H; Moezi M
Acta Haematol; 2024; 147(3):333-343. PubMed ID: 37778326
[TBL] [Abstract][Full Text] [Related]
8. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
9. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis.
Li T; Liu Q; Pu T; Liu J; Zhang A
Expert Opin Pharmacother; 2023 Apr; 24(6):763-774. PubMed ID: 37010022
[TBL] [Abstract][Full Text] [Related]
11. Avatrombopag: A Review in Thrombocytopenia.
Markham A
Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
[TBL] [Abstract][Full Text] [Related]
12. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
Zeng Y; Duan X; Xu J; Ni X
Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD008235. PubMed ID: 21735426
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.
Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
PLoS One; 2018; 13(6):e0198504. PubMed ID: 29856837
[TBL] [Abstract][Full Text] [Related]
14. Avatrombopag for the Treatment of Immune Thrombocytopenia and Periprocedural Thrombocytopenia Associated With Chronic Liver Disease.
Tran TB; Downing L; Elmes JB; Arnall JR; Moore DC
J Pharm Pract; 2024 Feb; 37(1):184-189. PubMed ID: 36113085
[No Abstract] [Full Text] [Related]
15. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
16. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
Maitland HS
Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
[TBL] [Abstract][Full Text] [Related]
17. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.
Zhang J; Liang Y; Ai Y; Li X; Xie J; Li Y; Zheng W; He R
Sci Rep; 2018 Jan; 8(1):576. PubMed ID: 29330464
[TBL] [Abstract][Full Text] [Related]
19. Romiplostim: a review of its use in immune thrombocytopenia.
Keating GM
Drugs; 2012 Feb; 72(3):415-35. PubMed ID: 22316355
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
Boyers D; Jia X; Crowther M; Jenkinson D; Fraser C; Mowatt G
Health Technol Assess; 2011 May; 15 Suppl 1():23-32. PubMed ID: 21609650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
